The retrospective study suggests that ...neoadjuvant chemotherapy may impact negatively the survival for patients with diffuse malignant peritoneal mesothelioma...
Raleigh, NC (PRWEB) August 01, 2016
Scientists studying the effects of various chemotherapy strategies on mesothelioma survival after CRS-HIPEC treatment now say presurgical chemotherapy can actually shorten survival instead of extending it. Surviving Mesothelioma has just posted an article on the group's new research. Click here to read it now.
The study involved 126 patients with diffuse malignant peritoneal mesothelioma who underwent cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) between 1991 and 2014.
“The retrospective study suggests that adjuvant chemotherapy may delay recurrence and improve survival and that neoadjuvant chemotherapy may impact negatively the survival for patients with diffuse malignant peritoneal mesothelioma who underwent CRS-HIPEC with curative intent,” writes the study’s lead author, Dr. Vahan Kepenekian with Lyon-Sud University Hospital.
The article, published in a recent issue of the European Journal of Cancer, found that only 40 percent of neoadjuvant chemotherapy patients were still alive five years later, whereas 56 percent of those who’d had no systemic chemotherapy survived for at least five years.
“These findings have the potential to improve mesothelioma survival by shedding valuable light on the question of whether and when peritoneal mesothelioma patients should consider systemic chemotherapy,” says Alex Strauss, Managing Editor of Surviving Mesothelioma.
To read more results from the French study and learn about the various chemotherapy strategies for patients with peritoneal mesothelioma, see Study Explores Treatment Strategies for Peritoneal Mesothelioma Survival, now available on the Surviving Mesothelioma website.
Kepenekian, V, et al, “DIffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study”, July 26, 2016, European Journal of Cancer, pp. 69-79, Epub ahead of print, http://www.sciencedirect.com/science/article/pii/S0959804916321918
For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.